AZD-1940

AZD-1940, also known as ART27.13 or NEO-1940, is a drug developed by AstraZeneca, that is a peripherally selective cannabinoid agonist which binds with high affinity to both the cannabinoid CB 1 and CB 2 receptors.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

AZD-1940, also known as ART27.13 or NEO-1940, is a drug developed by AstraZeneca, that is a peripherally selective cannabinoid agonist which binds with high affinity to both the cannabinoid CB 1 and CB 2 receptors. It was developed for the treatment of neuropathic pain, but while it showed good peripheral selectivity in animal studies, in human clinical trials it failed to show sufficient analgesic efficacy and produced unexpectedly strong side effects associated with central cannabinoid activity, and so was discontinued from further development.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1372016257 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.